Private investor who started at the age of 16 years old with a joint account with my dad. I'm now more than 50-years old. I came up through the finance ranks starting my career at Arthur Andersen & Co. I became a CFO of a private company in my early 30s and was lucky enough to be able to retire many years ago after being in the right place at the right time. I retired as the President of a $400 million partnership marketing company. My investment philosophy is to focus on companies that have the following characteristics:
- Rock solid balance sheets
- Outstanding FCFs
- Growing revenues
- Expanding margins
- Strong management team focused on driving LONG-TERM STAKEHOLDER VALUE!
I perform all my own due diligence and build all my own models. My motto is SLOW AND STEADY!!!
Parsimony Research provides dividend stock research and analysis to investors subscribed to the Dividend Investors Club. The Dividend Investors Club is made up of thousands of do-it-yourself dividend and income investors working toward one common goal...generating consistent income!
Our strategy is simple:
1. Buy great dividend stocks at reasonable prices.
2. Enhance income with conservative option strategies.
3. Manage risk through diversification and exit strategies.
Our research (which includes dividend stock rankings, online stock profiles, Buy Zones, Profit Zones, Action Ratings, stock screens, and model portfolios) will give you all the tools you need to build and monitor your own DIY Dividend Portfolio and super charge that portfolio with conservative option strategies (cover calls and cash-secured puts).
Visit the Dividend investors Club website to learn more...
I am a Civil Engineer, who is married with three kids under the age of 5. In early 2013 I took a more active role in managing my IRA for retirement and decided to publicly share my experiences in building the portfolio. My hope is to provide a positive example for other young do-it-yourself investors as they save for retirement on a limited budget.
My interest in investing mostly began in 2005 when I started up an investment club with a few friends from college and has accelerated as I've been reading and learning along the way. Since then, investing and the stock market has become a passion and favorite hobby and I've enjoyed writing about stocks and sharing ideas I have here on Seeking Alpha.
My investing goals are to build a nest egg for retirement and fund college education accounts for my kids. I invest mainly in dividend paying stocks that have shown a history of consistent growth in earnings and dividend payouts.
I would like to welcome you all to Dr. Tran BioSci Advisory. As a medical doctor and market expert, I'm well known in the market and the digital media community. For newcomers, I wish to share my background and missions for this consultancy. In 2013, I founded Retail Investor 360 and Vincata Enterprises LLC to help everyday investors and to assist life science firms to gain exposure to the investing community. In 2017, I launched Dr. Tran BioSci Advisory to fulfill a three-prongs mission: to innovate life-saving medicine for patients; to deliver differentiated market intelligence for investors; and to unlock premium valuations for firms.
Before graduate school, l worked in a cancer research lab as a research assistant at UNC-Chapel Hill. While working there, I gained my first-hand experience in the earliest phase of the drug development process. Thereafter, I dedicated a year as a teaching assistant for general and organic chemistry at UNC-Charlotte. This experience helped me to elucidates the intricacies of science in simple terms for all readers. In 2007, I earned a master of science degree at the Columbia University in New York, where I focused on the research relating to human nutrition and medicine. Through the Institute of Human Nutrition, I published as an author in the respectable Encyclopedia of Obesity along with the renowned Professor Kathleen Keller. The wisdom learned from top notched faculties at Columbia enabled me to gain invaluable insights into the efficacy and safety of developing therapeutics. In 2013, I received my doctoral degree from East Carolina University. The expertise as a medical doctor helped me to be cognizant of the prescribing patterns and the roles of medicine in disease management. Further, it enabled me to recognize the unfilled therapeutic needs as well as to gauge which innovating drugs are likely to achieve market success.
In finance, I've studied extensively from the works of world renown investors, not limited to Phillip Fisher, Benjamin Graham, Warren Buffett, John Templeton, Mohnish Pabrai, and Joel Greenblatt. Despite my reception toward the advancement in this digital information age, I adamantly adhere to the timeless fundamentals of intelligent investing. Leveraging on my diverse background, I pioneered the analytical methodology coined integrated research. This comprehensive style enabled me to accurately forecast clinical trials outcomes far in advance of the market. Notable studies include the Flint trials of Intercept Pharmaceuticals and the Ascend trials of InterMune Inc. Most firms that I covered in the previous years gained multiple folds for investors either through share price appreciation or complete acquisition. Key examples are Medivation, Jazz Pharmaceuticals, and Exelixis, Inc.
Through my work, I formed meaningful relationships with professional as well as retail investors, KOLs, and CEOs. And my research intelligence is well-respected by market leaders, policy makers, medical experts as well as investors. In the early days of market experimentation, I issued a few short articles. Nonetheless, I predominantly published long investing theses, as the rewards are most substantial. In testing the water with short theses publications as stated, I refined my skills in avoiding weak firms and in picking winners. Interestingly, my overall short accuracy has been more accurate than long. KOLs who short firms seek my counsel. And the rare short theses that I issued have yet to see daylight. Despite that I am bound to make more mistakes, I hope to continue a highly accurate track record of trial data analysis in the future. With much wisdom of a maverick as well as the invaluable experience gained in my rookie years, I'm now poised to publish mostly long thesis to unlock premium valuations. Asides my emphasis on the biopharmaceuticals industry, I will venture into other businesses as the opportunities arise. Thank you, and I look forward to providing stellar services as well as to learn from you.
Hung V. Tran, M.D., M.S., C.C.M.A.
"Stellar therapeutics for patients. Differentiated intelligence for investors. Premium valuations for firms."
Derek Getz is an individual investor seeking to navigate the investment world in order to provide a wealthy and stable retirement for his family. His aim is to help fellow investors, notably younger investors, establish a plan to produce a growing stream of income. Derek holds a Bachelor's degree in Computer Science with a minor in Economics from the University of Delaware and lives with his wife and two children.
Derek created and runs customstockalerts.com. It's a utility for investors to stay on top of all their stocks. Pick a company you are interested in, pick an alert type (price, dividend yield, PE, etc) and a value. You'll get a text or email (your choice) when your value hits.
There is also an ex-dividend utility, sending alerts when your companies are getting close to the big day. Use it as a chance to buy and collect the dividend!
Come check me out at customstockalerts.com and dividendderek.com!
Zach is a biotech investor with PhD training in Biochemistry and Molecular Biology. In real life, he is a scientific writer specializing in medical education. He hopes to provide a crucial piece of total due diligence as well as interesting insight into clinical findings that may impact readers' portfolios and lives.
I am an undergraduate student at the University of Oregon with a love for investing. As a risk-averse dividend growth investor I look for value among high yield players in the markets. Not specialized in any sector my writings cover a diverse group of securities and macro ideas.
I was born in Finland, raised in France and I have studied in Germany, the UK and the USA. I started managing my own portfolio at 14, founded my first company at 16 and later acquired my first real estate investment at 18. I have experience working in Private Equity Real Estate and therefore tend to mostly focus on REITs, REOCs, and other real asset heavy businesses. I am a CFA Level 2 Candidate and completed my university studies in Real Estate Finance and Investments.
My international background gives me a certain edge over other investors as it provides me a superior understanding of the differences between European and American markets and help me to identify superior opportunities in a broader universe of securities.
Don't hesitate to reach out and connect via LinkedIn.
DISCLAIMER: Jussi Askola is not a Registered Investment Advisor or Financial Planner. The Information in his articles and his comments on SeekingAlpha.com or elsewhere is provided for information purposes only. Do your own research or seek the advice of a qualified professional. You are responsible for your own investment decisions.
I am a retired engineering executive and a committed self-taught dividend growth investor. I am a proponent of "buy and hold" and reinvesting dividends to compound stock share count and dividend payouts. After decades of paying mutual funds to manage my retirement and taxable accounts, I now manage these funds entirely by myself and am fascinated by the never-ending learning process about investing, individual companies, their management and Mr. Market's behavior.
I have seriously studied Warren Buffett and his investing approach, as well as his methods of managing Berkshire Hathaway. I have been investing in high-quality dividend growth companies since 2001. I enjoy watching dividends grow and analyzing companies that managed to survive the Financial Crisis with minimal impact on earnings and dividends.
Former broker, now an independent analyst/writer on Seeking Alpha and founder and editor of the Growth Stock Forum. Focusing on small-cap, mid-cap and biotech stocks. Looking for substantial sales and earnings growth potential and seeking the best risk-adjusted returns from my stock selection. Taking advantage of medium to long-term momentum.
My articles represent my personal opinion and analysis and should not be regarded as investment advice in any way. Readers and subscribers should do their own due diligence and/or consult their financial advisor before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.
Exclusive research: http://seekingalpha.com/author/oneil-trader/research
Elephant Analytics has 15 years of analytical experience and unique skills in numerical analysis and practical mathematics. He achieved a top 50 score on the Bloomberg Aptitude Test measuring financial aptitude (out of nearly 200,000 test takers). He has also achieved a score (153) in the 99.98th percentile on the WAIS-III IQ test and has led multiple teams that have won awards during business and strategy competitions involving numerical analysis. In one such competition, he captained his team to become North American champions, finishing ahead of top Ivy League MBA teams, and represented North America in the Paris finals.
Elephant Analytics also co-founded a company that was selected as one of 25 companies to participate in an start-up incubator program that eventually spawned several companies with $100+ million valuations. He also developed the economic model for a mobile app that has generated over $1 million in revenue with minimal advertising.
Legal Disclaimer: Elephant Analytics' reports, premium research service and other writings are personal opinions only and should not be considered as investment advice. Only registered investment advisors can provide personalized investment advice. While Elephant Analytics attempts to provide reports that include accurate facts, investors should do their own diligence and fact checking prior to making their own decisions.
Investor/trader focused on discovering under the radar stocks and alpha generating ideas for my readers. Additionally, I try to give a differentiated take on names readers might already be familiar with. My specialty is looking specifically for opportunities to achieve high % gains within a year's timeframe (ROTY- Runners of the Year). Last but not least, I highlight risk management and entry/exit strategies quite a bit, as I believe they represent areas that are often neglected but materially important for readers to understand and apply.
TipRanks Top 150 First Half 2017 (Top 100 First Quarter)
My biggest successes have been in the biotech arena (over $300k personal portfolio profits), while my biggest losses have been due to overconfidence and a failure to adequately heed the bear thesis on my picks.
As always, all posts are my personal opinion. None of my material should be considered as investment advice, as readers must make their own decisions based on their own financial situations or are encouraged to utilize an investment professional (CFP, etc). Trading and investing in stocks can be very risky, and investors can lose up to 100% of principal in the event of adverse circumstances. By reading my material readers are agreeing to the above and assuming all responsibility for their own investment decisions.
FAQ (Frequently Asked Questions)
1: Why don't you have positions in each of the ROTY model account ideas?
It's a great question, one I've been getting recently and good for those who have asked it. Long story short, I've cashed out the majority of my portfolio, including gains from previous years, to buy a condo here in Peru, the kind I've always wanted but never thought I'd be able to afford. I'm very thankful for where trading and investing has taken me up to this point. I also used the funds with my wife to start her retail clothing chain, one which has a unique premise and wide moat. After we finish furnishing the place as well as get her business into a dominant self-sustaining position, I plan to turn future cashflow toward ROTY investing. The scalable ROTY model account is a transparent manner for me to show readers in real-time how I would be going about my trades in hopes that they find it useful, regardless of their account size.
2: What should I do if a binary catalyst or key event is coming for a stock that I own?
Again, I don't give advice, but what I would do personally depends on the situation. In general we try to purchase stocks months or even over a year out before such an event happens, so that we can "play the runup". If for example a stock rises 50% prior to the event, an investor can take full profits (sell the position) before the event if he or she has low risk tolerance (ie. doesn't want to lose money). If the investor has higher risk tolerance (I'm in this category generally), he or she can take partial profits (ie. sell 25% to 75% of shares) and hold the rest. If the trial data is positive or treatment is approved by the FDA or earnings are outstanding, then the investor will enjoy that big gain and bank the money. However, if the event has a disappointing result, at least you've already locked in gains and lose less. Just my two cents and how I typically operate.
Editor for The Biotech Forum & The Insiders Forum; two of the most subscribed to services available via SeekingAlpha's MarketPlace. Long time Real Money Pro contributor. Biotech investor for a quarter century and frequent speaker on the topic at investment conferences like the MoneyShow and in interviews. For FREE weekly investment reports on small, attractive biotech stocks just register at biotechfreereports.com. To get my articles and instablogs as soon as they are published, please hit my profile and become a real-time follower.
As director of research at Portfolio123, I have long specialized in rules/factor-based equity investing strategies of the sort characterized as “Smart Alpha” in the July 2014 Journal of Portfolio Management. In addition, I formerly managed a high-yield fixed-income fund and conducted research involving quantitative asset allocation strategies such as are at the foundation of what today has come to be known as Robo Advising. I formerly edited the the Forbes Low Priced Stock Report, and served as an assistant research director at Value Line. I have long had a passion for investor education, which has resulted in my having conducted numerous seminars on stock selection and analysis, and the authoring of two books: Screening The Market and The Value Connection.
"One of the best ways to do well in this business is to go to areas that have been unexploited by research capability and work them for all you can." -Julian Robertson
Bram de Haas lives with his girlfriend and baby son in The Netherlands/Nijmegen. Living in a city once a Roman settlement later bombed by allied forces in WO II he is aware of the vulnerability of Empires and the impact of the unexpected.
His investment style can be summed up as safety first. Once safe: be agressive.
The resource referenced below can be deceptively inaccurate, and does not weed out all of the harmful bloggers. It is better than nothing in its attempt to track the performance of stocks written about through Seeking Alpha. If you use a benchmark then some of the emphasis on "Recommendation count" is offset. https://www.tipranks.com/bloggers/prescient-investment-analysis?benchmark=snp500&period=yearly Important information follows, please click the link below to review it all:
Work presented may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but instead represent only the author's belief regarding future events, many of which, by their nature, are inherently uncertain and outside his control. Except for the author's obligation to disclose material information, the author is not under any obligation (and expressly disclaims any obligation) to update or alter any projections, goals, assumptions, or other statements, whether written or oral, that may be made from time to time, whether as a result of new information, future events or otherwise.
No content within the author's work is a recommendation that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person or purpose. The author is not advising you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. To the extent that any of the content of this article may be deemed to be investment advice or recommendations in connection with a particular security, such information is impersonal and not tailored to specific investment needs. The author is not an investment advisor and is not offering investment advice. You understand that an investment in any security is subject to a number of risks, and that discussions of any security published will not contain a list or description of relevant risk factors. Some of the stocks about which the author has written and writes about have a low market capitalization and/or insufficient public float. Such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information. Any information in the author's work deemed by you to be recommendations may have an effect on their stock prices.
The author's publications are not intended to provide tax, legal, insurance or investment advice, and nothing presented in the author's work should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Seeking Alpha or any third party. You alone are solely responsible for determining whether any investment, security or strategy, or any other product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. You should consult an attorney or tax professional regarding your specific legal or tax situation.
All information in this report is provided "as is" without warranty, expressed or implied, or representations of any kind to the fullest extent permissible under applicable law, the author will not be liable for the quality, accuracy, completeness, reliability, or timeliness of this information, or for any direct, consequential, incidental, special or punitive damages that may arise out of use of this information by you or anyone else, including but not limited to lost profits, loss of opportunities, trading losses, and damage that may result from any inaccuracy or incompleteness of this information to the fullest extent permitted by law. The author denies liability to you or anyone else under any tort, contract, negligence, strict liability, products liability, or other theory with respect to presentation of information.
The information, opinions, data, quantitative and qualitative statements communicated have been obtained from sources believed to be reliable but have not been independently verified and are not guaranteed as to accuracy nor does it purport to be a complete analysis of every material fact regarding the company, industry, or security. The information, opinions, or recommendations are solely for informational purposes and are only valid as of the date appearing on the report and are subject to change without notice. You recognize that performance data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that such calculations are not guaranteed by these sources, the information providers, or any other person or entity, and may not be complete.
The author writes about and invests in high risk companies, some of which succeed, and some of which go out of business completely, rendering securities, including bonds, preferred stock, common stock, options and other financial derivatives valueless.
The author does not intend to receive any inside information from any of the companies written about.
Investors are encouraged to read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.
Prescient Investment Analysis is a person. BA, Boston College, Philosophy.
Lakshmi Janardhan, President of Business Integrations Inc., has a background in technology and business ethics and holds bachelors in Computer Science, Math & Engineering from University of Illinois and a Masters in Computer Science from Wayne State University in Detroit, Michigan. Lakshmi focuses in investments and trading of bio-technology, computer, computer services, energy and automotive sectors. Lakshmi is a trader/investor and has over 20+ years’ experience in trading and investing in micro, small, mid-large caps. From being a novice trader before the technology boom in the late 90’s to being a more mature and conservative investor in recent days, her analysis has helped other traders. She often works with her husband Murali Sarma in developing ideas for trading and investments. Lakshmi has helped several traders become successful over the last 10+ years of active stock and futures trading and has a strong following of friends and family of traders who like to seek out opportunities in the futures markets on a daily basis versus following the old “buy & hold” investing adage. While not being opposed to switching hats and becoming an “investor” every so often with swing trades in the equities markets, Lakshmi prefers to trade what he can see on charts using multiple timeframes and handcrafted indicators suited for all types of markets. Lakshmi excels in trading sideways and choppy markets with a scalping style of being in-out of intraday markets when there is no defined trend, and on most other days prefers trading to his own computed target levels during the intraday timeframe, while following the trend.
In recent months, Lakshmi, with her husband Murali Sarma, have started a screen share opportunity for intraday futures traders who like to trade commodities and index futures, and elected to blog post his daily analysis in commodities like WTI Crude & Gold and index future instruments like YM, NQ, ES & TF. You may contact them via posts on his blog at https://www.wtitrader.com.
Author of Tipswatch.com blog, David Enna is a long-time journalist based in Charlotte, N.C. A past winner of two Society of American Business Editors and Writers awards, he has written on real estate and home finance, and was a founding editor of The Charlotte Observer's website. The Tipswatch blog, which launched in April 2011, explores ideas, benefits and cautions about Treasury Inflation-Protected Securities, which David believes are an under-appreciated and under-used investment. David has been investing in TIPS and I Bonds since 1998.
Gary A. Gordon, MS, CFP® is the president of Pacific Park Financial, Inc., a Registered Investment Adviser with the SEC. He has more than 28 years of experience as a personal coach in “money matters,” including risk assessment, small business development and portfolio management. He favors tactical asset allocation strategies over "set-it-and-forget-it" investing.
Gary is often asked to consult as an educator. He has taught financial concepts in Mexico, Singapore, Hong Kong, Taiwan and the United States.
As a Certified Financial Planner™ (CFP®), Gary has distinguished himself as a reputable and trusted investor advocate. He writes commentary for ETF Expert, Seeking Alpha and The Street. Gary’s participation on local and national radio has spanned more than two decades, and he currently hosts the ETF Expert Show.
Gary is a “good sport” when his wife, Denise, beats him at Scrabble. Most of all, Gary takes special pride in a not-so-little energizer… his 20-year old daughter, Wei Gordon.
I am a 40 year old investor with a long term perspective and a lot of patience. I mainly think about the future when investing in stocks. I do not care about what my selection of stocks will do next year, but what the result will be in 2040 or so. To paraphrase Warren Buffett: "You should only have stocks that you would feel comfortable having if the stock market closes up for 10 years." That means that I look for stocks that combine growth and value. It has been proven that the group of dividend initiators and fastest dividend growers outperforms the markets by far in the long run. So I mainly select stocks from this group, although I also select some non-dividend payers that I believe will grow out to great future value players. Hence: from Growth to Value. I appreciate your comments, because I believe I can learn a lot from your feedback and I believe in the wisdom of crowds.
I am formally a data analyst for a non-financial services organization. I have an undergraduate degree in business and a masters degree in predictive analytics. My background as an investor has been in setting and forgetting my 401k. In my recent job change I was enlightened to not having a plan for retirement. In my waking up, I have decided to start posting on Seeking Alpha to help encourage others to have a similar awakening as well as receive feedback from all the great contributors to the site.
Also, Doctor Dividend and I have started a podcast. You can check out our episodes here:ITunes: https://itunes.apple.com/us/podcast/dividend-health-checkup/id1086182519?mt=2Sound Cloud: https://soundcloud.com/dividend-health-check-up
Hoya Capital Real Estate is a Connecticut-based Registered Investment Advisor that focuses on research of the commercial real estate industry, and advisory of well-balanced public real estate equity portfolios.
All of our research is for educational purpose only, always provided free of charge exclusively on Seeking Alpha. Recommendations and commentary are purely theoretical and not intended as investment advice. Information presented is believed to be factual and up-to-date, but we do not guarantee its accuracy and it should not be regarded as a complete analysis of the subjects discussed. For investment advice, consult your financial advisor.
Retired; (BDC, mREIT) 50/50 Portfolio; dividends at 76% of my gross employment income. I created a High Yield Investment dividend generator that contains a 50% weighting between agency mortgage REITs and BDCs.
**** Retired 2017 ****Retired 2017 ****Retired 2017 ****Retired 2017 ****
My current investment method started January 2014 to concentrate on high yield equities that put more importance on income and less on capital appreciation. Investment purchase is based on each individual stock generating a minimum dividend per year. As long as stocks are generating income to meet or exceed my minimum dividend they will not be added too or removed.
1) Currently surplus dividends are reinvested back into stocks that require their dividends to be increased to meet my minimum yearly dividend. Since retiring in 2017 I have set up withdraws based on 50% of total cash flow income generated increasing at 3% per year.
2) The investment selection is based on this principle; BDCs outperform when markets are going up (positive correlation), and mREITs, outperform when markets are going down (negative correlation).
3) Capital gain does not apply to my investment method since this implies the anticipation of buy and hope for price increase in order to sell at a profit. Income cash flow is the main driver of my investment method in retirement. Portfolio balance will naturally increase since I'll always be in the accumulation phase.
Ian worked for Kerrisdale, a New York activist hedge fund, for three years, before moving to Latin America to pursue entrepreneurial opportunities there. His Ian's Insider Corner service provides live chat, model portfolios, full access and updates to his "IMF" portfolio, along with a weekly newsletter which expands on these topics.
Ian is also an associate analyst for Value Investor's Edge. VIE is a top-ranked deep value research service featuring exclusive work from J Mintzmyer, James Catlin, and Ian Bezek.
Ted Waller is a private investor who bought his first stock at age 13 (GTE) and has over 50 years of investing experience. His focus is on deep value and low risk. Acquiring wealth is a slow incremental process that requires setting goals, adherence to principles, patience, and flexibility.
Simply Safe Dividends helps conservative dividend investors increase current income, make better investment decisions, and avoid risk. Brian Bollinger, CPA, runs Simply Safe Dividends and previously worked as an equity research analyst at a multibillion-dollar investment firm.